




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>A61K 37/00, C07K 5/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/08815</b>  <b>(43) International Publication Date:</b> 13 May 1993 (13.05.93)
<b>(21) International Application Number:</b> PCT/US92/09114 <b>(22) International Filing Date:</b> 21 October 1992 (21.10.92)  <b>(30) Priority data:</b> 783,518                      28 October 1991 (28.10.91)      US  <b>(71) Applicant:</b> CYTOVEN [US/US]; 1309-114th Avenue, S.W., Suite 201, Bellevue, WA 98004 (US).  <b>(72) Inventors:</b> KHAVINSON, Vladimir Khatskelevich ; Begovaya, 7-1-251, St. Petersburg, 197198 (RU). MOROZOV, Vyacheslav Grigorievich ; Zoologicheskoy Pereulok, 1/3-83, St Petersburg, 197198 (RU). YAKOVLEV, German Mikhailovich ; ul. Komissara Smirnova, 8-50, St. Petersburg, 194175 (RU). SERY, Sergey Vladimirovich ; 3rd Rabfakovsky Per., 12/2-11, St. Petersburg, 193012 (RU).		<b>(74) Agent:</b> KENNEY, J., Ernest; Bacon & Thomas, 625 Slaters Lane, Fourth Floor, Alexandria, VA 22314 (US).  <b>(81) Designated States:</b> AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>

**(54) Title:** PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF

**(57) Abstract**

Methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient the dipeptide L-Glu-L-Trp, the cyclic monomer thereof, polymers thereof of the formula  $\text{H}_2\text{N} - \text{[L-Glu-L-Trp]}_n - \text{CO}_2\text{H}$ ; cyclic polymers thereof of formula (I) and their pharmaceutically acceptable salts thereof, wherein n and m are independently  $\geq 2$ .

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

-1-

PHARMACEUTICAL DIPEPTIDE COMPOSITIONS  
AND METHODS OF USE THEREOF

The present invention is directed to dipeptide pharmaceutical compositions and uses thereof, in particular, uses thereof for treatment of immunodepressed states and of opportunistic infections in immunodepressed states.

BACKGROUND OF THE INVENTION

Several polypeptides found in the thymus gland have been implicated as playing roles in the development and maintenance of immunological competence in animals, including human beings. Some of these polypeptides have been shown to stimulate the maturation, differentiation and function of T-cells. For example, a heat-stable fraction isolated from calf thymus extracts, designated as Thymosin fraction 5, has been shown to reconstitute immune functions in thymic-deprived or immunodepressed individuals. Several peptides have been isolated from Thymosin fraction 5, such as Thymosin alpha<sub>1</sub> (28 amino acids, U.S. Patent No. 4,079,127), Thymosin beta<sub>4</sub> (44 amino acids, Low et al., PNAS, 78,1162-1166 (1981)), Thymosin beta<sub>8</sub> (39 amino acids, U.S. Patent No. 4,389,343) and Thymosin beta<sub>9</sub> (41 amino acids, U.S. Patent No. 4,389,343). However, practical administration of such polypeptides is expensive due

-2-

to the relatively low yield and complexity of isolation and/or manufacture of such long chain polypeptides. Most importantly, in some cases, these polypeptides produce side reactions in patients.

5     The present invention is based in part on the discovery that a dipeptide, hereinafter referred to as Thymogen, exhibits a broad range of efficacy for prevention and treatment of opportunistic infections in immunodepressed states, and for therapeutically  
10 effective treatment of immunodeficient states. This is believed to be highly unexpected for such a relatively small compound to exhibit such a broad range of activity. Furthermore, we have not found any significant side effects from the use of the  
15 dipeptide according to the present invention. Due to its simple nature, the dipeptide is rather inexpensive to manufacture.

As used herein, the terms "immunomodulator" and "immunomodulating" encompass the activity of  
20 enhancing or restoring the subject's immune system, as evidenced by measurable blood parameters and/or the patient's improved ability to combat infection or disease, and the ability to heal tissue. Hence, immunomodulation encompasses improvement of the  
25 immune system due to an immunodeficient state (for example, caused by removal of the thymus), and/or an immunodepressed state (for example, caused by exposure to radiation). Furthermore, the present invention provides for modulation of the immune  
30 system by lowering blood parameters and other indicia of the immune state if these indicia are abnormally elevated. The present invention encompasses the therapeutic method of treating the immunodeficient, immunodepressed or elevated immune state per se, thus  
35 providing prophylaxis against infection and disease,

-3-

as well as a treatment of infection, disease or wound indirectly by enhancing the immune system.

- It is therefore an object of the present invention to provide pharmaceutical compositions of the
- 5 dipeptide Thymogen which have broad immunomodulating activity, as well as activity for other uses such as treatment of infections, disease and wounds (burns, frost bites, and the like), enhancement of metabolic processes, and many other uses.
- 10 It is an object of the present invention to provide therapeutic methods for treatment of immunodepressed and immunodeficient states.

- It is yet another object of the present invention to provide methods for preventing and treating
- 15 opportunistic infections in immunodeficient and immunodepressed states.

These and other objects will be apparent from the following description and appended claims.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

- 20 The present invention provides pharmaceutical preparations comprising the dipeptide L-Glu-L-Trp, including cyclic forms and linear and cyclic polymers of the dipeptide, using the normal convention wherein the first named amino acid is the amino terminus and
- 25 the last named amino acid is the carboxyl terminus. For convenience, all forms will be collectively referred to herein as "the dipeptide". The compositions containing the dipeptide according to the present invention may be formulated into any
- 30 convenient formulation which allows for the active ingredient to be absorbed into the blood stream.

-4-

Intramuscular and intranasal forms of application are preferred. The preferred dosage rate of the active ingredient for intramuscular administration is about 50 to 100 $\mu$ g per dose for adults (for a 300 to 1000 $\mu$ g total treatment therapy); for infants up to 1 year old about 10 $\mu$ g per dose, for infants 1 to 3 years old about 10 to 20 $\mu$ g per dose; for infants 4 to 6 years old about 20 to 30 $\mu$ g per dose, for children 7 to 14 years old about 50 $\mu$ g per dose. All of the foregoing dosages are useful for a treatment of 3 to 10 days, depending upon the immunodeficiency level. The treatment may be repeated as needed, usually within 1 to 6 months.

For prophylactic uses against opportunistic infections in immunodeficient or immunodepressed patients, the intramuscular and/or intranasal single daily dose for adults may be from about 50 to 10 $\mu$ g, and for children about 10 to 50  $\mu$ g per dose for treatment over 3 to 5 days.

For treatment of burns, frost bite, or other wounds, including chronic apical periodontitis, the dipeptide may be applied in about 100 $\mu$ g doses as a paste or other suitable medium.

For ophthalmology, such as for treatment of infectious eye diseases, the dipeptide may be applied in single daily dosages of about 10 $\mu$ g (over 4 to 10 days) or as installations into the conjunctival cavity at about 5 $\mu$ g twice daily over about 4 to 5 days.

The dipeptide may be utilized intramuscularly as an injection solution with the active ingredient in a therapeutically effective immunopotentiating amount of about .001 to .01% by weight. If presented in the

-5-


form of a tablet, capsule or suppository it is preferred that the active ingredient be present in an amount of about 0.1mg per tablet, suppository or capsule. If presented in such form, the capsule, 5 suppository or tablet may also contain other conventional excipients and vehicles such as fillers, starch, glucose, etc.

The dipeptide may be obtained by conventional peptide synthesis, including the Merrifield solid 10 state peptide synthesis technique. Typically an amino and side chain protected derivative of an activated ester of glutamic acid is reacted with protected L-tryptophan. After elimination of the protecting groups and conventional purification, such 15 as by thin layer or GL chromatography, the peptide may be purified such as by, lyophilization, gel purification, and the like.

The purified dipeptide L-Glu-L-Trp, comprises a white powder (if lyophilized; otherwise, it is 20 crystalline), soluble in water, DMF; insoluble in chloroform and ether.  $[\alpha]_D^{22} = +12.6$ ;  $C = 0.5$  H<sub>2</sub>O.  $R_f = 0.65$  (butanol: acetic acid: water = 3:1:1). UV ( $275 \pm 5$ nm, max). NMR (500MHz): 0.001mol/l of the peptide solution, Trp (3.17; 3.37; 25 4.57; 7.16; 7.24; 7.71; 7.49); Glu (1.90; 1.96; 2.21; 3.72).

-6-


Other forms of the dipeptide are also encompassed by the invention, including the cyclized monomer.



Wherein R' and R'' are, respectively, the alpha-side chains of Glu and Trp;

5 Linear polymers  $\text{H}_2\text{N}-[\text{Glu-Trp}]_n-\text{CO}_2\text{H}$ ,  $n \geq 2$

and cyclic polymers



10

all of these forms, including the dipeptide monomer, will be referred to as the "dipeptide". The linear polymers may be made by conventional peptide synthesis, including Merrifield solid-state peptide methodology. The cyclic monomer and polymers may be prepared by cyclizing the linear peptide in with peptide linkage agents in dilute solutions.

The active dipeptide ingredient of the pharmaceutical preparations according to the present invention may be used as a free peptide or in the form of a water soluble pharmaceutically acceptable salt, such as a sodium, potassium, ammonium or zinc salt. It will be understood that the dipeptide may be administered with other active ingredients which independently impart an activity to the composition, such as, antibiotics, interferon, anesthetics, and the like.



-7-

The most preferred formulation according to the present invention is a solution for intramuscular injection containing about .001 to .01% by weight (.0001-.001mg/kg body weight, or 10-100 $\mu$ g active ingredient per 1ml solvent). The pharmaceutically acceptable vehicle for this injection form may be any pharmaceutically acceptable solvent such as 0.9% aqueous sodium chloride, distilled water, Novocaine solution, Ringer's solution, glucose solution, and the like. The dipeptide containing compositions according to the present invention may be administered in a compatible pharmaceutical suitable for parenteral administration (e.g., intravenous, subcutaneous, intramuscular). The preparations may be subjected to conventional pharmaceutical operations, such as sterilization, and may contain adjuvants, such as preservatives, stabilizers, wetting agents and the like.

The pharmaceutical preparations according to the present invention demonstrate a high effectiveness in the treatment of immunodepressed and immunodeficient states for the preventing and treatment of opportunistic infections in those states.

Also included within the scope of the present invention are the pharmaceutically acceptable salts of the dipeptide, such as sodium or potassium or strong organic bases, such as guanidine.

The dipeptide containing compositions according to the present invention have activity in the restoration and stimulation of the immune functions. Thus they are useful in the treatment of opportunistic infections of an immunodepressed subject in an immunopotentiating effective amount as described above.

-8-

The dipeptide compositions according to the present invention may also be used in veterinary practice as an immunomodulatory agent for prophylaxis and treatment of hypotrophy in farming  
5 animals, fur bearing animals and poultry.

Among the opportunistic infections which may be treated utilizing the compositions according to the present invention are: respiratory diseases, influenza, AIDS, burns, wounds, other open sores,  
10 rashes (due to allergic reactions), sun exposure, local trauma (with an ointment), eczemas, psoriasis, and the like. Furthermore, the compositions according to the present invention may be utilized to assist healing in immunodepressed or immunodeficient  
15 states, such as for the healing of bone fractures, lesions, gingival diseases, gynecological infections, infralymphatic infections, and the like. The compositions may also be used to enhance the immunodeficient state to increase susceptibility to  
20 microbial antibiotics and to enhance the patient's responsive reaction to other types of therapies.

The compositions according to the present invention also may be utilized to enhance metabolic processes; to enhance production of blood insulin;  
25 for treatment of irradiated cancer patients, as well as for veterinary uses.

Another important use is the treatment of chronic fatigue syndrome (CFS), which is believed to be a manifestation of an immunodepressed state.

30 The following examples are provided to further elucidate the invention, but are not intended to restrict the invention in scope or spirit in any way.